Association between interleukin 6 promoter variants and chronic hepatitis B progression.
- Author:
Byung Lae PARK
1
;
Hyo Suk LEE
;
Yoon Jun KIM
;
Jun Yeon KIM
;
Ji Hyun JUNG
;
Lyoung Hyo KIM
;
Hyoung Doo SHIN
Author Information
1. Department of Genetic Epidemiology SNP Genetics, Inc., 11 th Floor, Maehun B/D 13 Chongro 4 ga, Chongro-gu, Seoul 110-834, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
carcinoma;
hepatocellular;
haplotypes;
he-patitis B virus;
interleukin-6;
polymorphism;
single nu-cleotide;
promoter regions (genetics)
- MeSH:
Aged;
Alleles;
Asian Continental Ancestry Group/genetics;
Female;
Haplotypes/genetics;
Hepatitis B, Chronic/*genetics;
Human;
Interleukin-6/*genetics;
Korea;
Linkage Disequilibrium;
Male;
Middle Aged;
Polymorphism, Single Nucleotide/genetics;
Promoter Regions (Genetics)/*genetics;
Variation (Genetics)/*genetics
- From:Experimental & Molecular Medicine
2003;35(2):76-82
- CountryRepublic of Korea
- Language:English
-
Abstract:
Interleukin 6 (IL6) plays an essential role in the regulation of immune response to chronic disease. In this study, the three known single nucleotide polymorphisms (SNPs) in the IL6 promoter region were genotyped in a large chronic hepatitis B cohort to evaluate the effects of IL6 promoter variants. The single base extension method was used for this genotyping. Haplotypes were constructed by the three SNPs in IL6. Allele frequencies were compared for; i) patients with chronic hepatitis (CH) and chronic carriers vs. chronic hepatis patients with clinical evidence of liver cirrhosis (LC) (i.e., portal hypertension), ii) cirrhotic patients with hepatocellular carcinoma (HCC) vs. without HCC by logistic regression, and iii) with respect to the time intervals from the onset of infection to HCC. Results were analyzed by Cox relative hazard analysis on the assumption that all the patients were infected during early infancy. The frequencies of each SNP were 0.002 (IL6-597 G>A), 0.25 (IL6-572 C>G) and 0.002 (IL6-174 G>C), respectively, in the Korean population (n = 1,046). No significant associations were detected between IL6-572 C>G and chronic hepatitis B outcome in this study; i.e., chronic hepatitis B outcome in this study; i.e., LC occurrence on CH (OR = 0.16-1.27, P = 0.13- 0.71) and HCC occurrence on LC (OR = 1.04-1.23, P = 0.89-0.60) of heterozygotes and homozygotes for G allele in referent comparison to homozygotes for common allele (C/C genotype), and time interval to HCC (RH = 0.67-1.00; P = 0.14-0.99). In conclusion, there appeared to be no significant associations between IL6 promoter variants and disease outcome in chronic hepatitis B.
